Kailera's U.S. IPO validates Hengrui's global monetization path for GLP-1 assets

Overview

This report comments on the launch of a U.S. IPO by NewCo Kailera, in which Hengrui holds a 13.6% stake. Kailera owns the ex-China rights to Hengrui's GLP-1 portfolio and plans to raise approximately US$625mn through the issuance of 39.10 million shares at US$16 per share. Morgan Stanley believes this event validates Hengrui's path to global monetization of its GLP-1 franchise through overseas capital markets, licensing rights, milestone payments, and sales royalties.

Core views

The core view is that the Kailera IPO may not only bring new investment gains to Hengrui in 2Q26, but also improve market visibility on Hengrui's innovative drug overseas expansion and the value of its GLP-1 pipeline. The report maintains Jiangsu Hengrui as a Top Pick and an Overweight rating, with a target price of HK$92.00, implying 39% upside.

Analysis framework

The report analyzes the situation by combining event catalysts, pipeline progress, valuation methodology, and financial forecasts: on one hand, it assesses the impact of Kailera's financing and IPO on Hengrui's investment gains and subsequent rights; on the other hand, it tracks the clinical milestones of ribupatide and related GLP-1/GIP, small-molecule GLP-1, and GLP-1/GIP/Glucagon triple-target products. Valuation is primarily based on DCF, with SOTP used for cross-checking.

Methodology notes

• Valuation methodsDCF

  discounted cash flow valuation

  The report assumes a WACC of 8.2%, a cost of equity of 8.1%, a terminal growth rate of 3.5%, and uses a 1.13x RMB/HKD conversion.

• Valuation methodsSOTP cross-check

  sum-of-the-parts cross-check

  The generics business is benchmarked at 10x 2025e P/E; domestic potential for innovative drugs is estimated at a 3.0-3.5x P/S range based on 2030 peak sales.

• research_modelMorgan Stanley ModelWare

  Morgan Stanley research model framework

  Unless otherwise specified, the key financial and valuation metrics in the report are based on the Morgan Stanley ModelWare framework.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Jiangsu Hengrui (1276.HK)

  Covered company, holding a 13.6% stake in Kailera and retaining related economic rights.

  Strengths

  Clear innovative drug overseas expansion logic; GLP-1 assets can be monetized through investment gains, milestones, and sales royalties; rated Overweight and designated as a Top Pick.

  Weaknesses

  Valuation depends on pipeline progress, financing conditions, and commercialization delivery; some traditional drugs still face centralized procurement pressure.

  Comparison

  The report uses the 2030 P/S ranges of China pharma peers and leading China biotech companies as references for SOTP cross-checking.

  Risks

  Pipeline progress falls short of expectations, drug sales underperform expectations, and VBP impact exceeds expectations.

• Kailera

  Platform for Hengrui's ex-China GLP-1 rights, now launching a U.S. IPO.

  Strengths

  Has completed multiple large funding rounds and is advancing toward a U.S. listing, with rights to global GLP-1-related pipelines.

  Weaknesses

  Still in the stage of clinical advancement and capital-market validation, with commercialization revenue not yet fully realized.

  Comparison

  Its IPO provides external market pricing and financing benchmarks for Hengrui's GLP-1 assets.

  Risks

  IPO pricing, clinical results, regulatory approvals, and the global GLP-1 competitive landscape may all affect value realization.

• ribupatide (KAI-9531)

  Kailera's core GLP-1/GIP dual receptor agonist asset.

  Strengths

  The injection is in global Ph3 and Ph2b stages, and the China NDA has been submitted; the oral version is planned to begin global Ph3 as early as 1H27.

  Weaknesses

  Key clinical data and approvals are still pending, and high-dose data will require further validation into 2027.

  Comparison

  Positioned in the global GLP-1/GIP competitive arena, it needs to be compared with peer weight-loss and metabolic drugs on efficacy, safety, and dosing convenience.

  Risks

  Ph3 or Ph2b data fall short of expectations, approval delays, and intensified commercialization competition.

• KAI-7535

  Oral small-molecule GLP-1 receptor agonist pipeline.

  Strengths

  The oral small-molecule format has potential dosing convenience advantages.

  Weaknesses

  Still at a relatively early clinical stage.

  Comparison

  Versus injectable and oral peptide GLP-1 options, differentiation depends on efficacy, safety, and adherence.

  Risks

  Ph2 topline data in 2027 may fall short of expectations.

• KAI-4729

  GLP-1/GIP/Glucagon triple receptor agonist pipeline.

  Strengths

  The triple-target mechanism offers potential differentiation.

  Weaknesses

  Still around the start of global Ph1, with clinical validation at an early stage.

  Comparison

  Compared with dual-target assets, its potential efficacy and safety require more clinical data to prove.

  Risks

  Insufficient early-stage clinical safety, tolerability, or efficacy signals.

Key data

• Kailera IPO fundraising sizeUS$625mnPlanned issuance of 39.10 million shares at US$16 per share.
• Hengrui's stake in Kailera13.6%Kailera is the NewCo platform for Hengrui's ex-China GLP-1 rights.
• Kailera previous financingUS$400mn Series A; US$600mn Series BSeries A was completed in October 2024, and Series B was completed in October 2025.
• Potential investment gainsNew investment gains may be recognized in 2Q26The report mentions that about Rmb400mn of gains related to the 2025 Series B had already been recognized.
• Rating and target priceOverweight; HK$92.00Current price HK$66.40, implying 39% upside.
• 2026e EPSRmb1.34Shown in the report table under Morgan Stanley methodology forecasts.
• 2026e revenueRmb35,862.8mnRevenue forecasts for 2025-2028 show a growth trend.
• Core pipeline ribupatide injectionGlobal Ph3 registration dose; Ph2b high doseThe NDA has been submitted in China, with approval expected around early 2027.

Impact & implications

Kailera's U.S. IPO provides capital-market validation for the overseas commercialization of Hengrui's innovative drug assets, helping to improve external valuation benchmarks for the GLP-1 pipeline and potentially bringing Hengrui incremental investment gains, future milestone payments, and sales royalties. If the clinical development and approvals of core GLP-1 assets progress as planned, Hengrui's innovative drug mix and international valuation logic could be further strengthened.

Risks

• The impact of VBP on products such as iodixanol, sevoflurane, and butorphanol may exceed expectations.
• Major setbacks in pipeline advancement could lead to unmet market expectations.
• Approval timing for innovative drugs may be slower than expected.
• Drug sales growth may come in below expectations.
• Changes in Kailera's IPO, financing conditions, or the overseas GLP-1 competitive landscape may weaken the monetization potential of the assets.

What to watch

• Kailera's final U.S. IPO issuance size, pricing, and post-listing performance.
• Whether Hengrui recognizes new investment gains related to Kailera in 2Q26.
• Progress of ribupatide injection global Ph3, Ph2b high-dose data, and China NDA approval.
• Whether oral ribupatide starts global Ph3 on schedule in 1H27.
• Ph2 topline data for KAI-7535 in 2027.
• Whether KAI-4729 starts global Ph1 in 2026 and discloses topline data in 2027.
• Whether Hengrui's subsequent licensing deals, collaboration income, and innovative drug sales growth exceed expectations.